SanBio Obtains Marketing Approval for "AKUUGO® Suspension for Intracranial Implantation" (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)

TOKYO, July 31, 2024--SanBio Co., Ltd. (TOKYO:4592) (head office: Tokyo, representative director & CEO: Keita Mori) hereby announces that today on July 31 2024, it obtained conditional and time-limited marketing approval for the human somatic stem cell-processed product "AKUUGO® suspension for intracranial implantation" (INN: vandefitemcel; hereafter, "AKUUGO®") in Japan, for the indication of improving chronic motor paralysis resulting from traumatic brain injury.